A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer
- Clamp, A.
- Adams, M.
- Atkinson, R.
- Boven, E.
- Calvert, A.H.
- Cervantes, A.
- Ganesan, T.
- Lotz, J.
- Vasey, P.
- Cheverton, P.
- Jayson, G.C.
ISSN: 0090-8258
Any de publicació: 2004
Volum: 95
Número: 1
Pàgines: 114-119
Tipus: Article